Clinical Trials

Advanced Non-small Cell Lung Cancer

NCT04974879 2023-03-29

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

20 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05104281 2023-03-29

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

60 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02504346 2023-03-28

TREM

200 enrolled

Lung Neoplasms

NCT05785208 2023-03-27

TEMPLE-2

Phase 4 Unknown

122 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04391283 2023-03-17

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

500 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04811001 2023-02-21

CAPLAND

170 enrolled

NSCLC

NCT05583409 2022-10-17

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Phase NA Unknown

72 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05458726 2022-07-26

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05085054 2022-05-20

Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02824952 2021-11-18

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02736513 2021-09-02

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases

40 enrolled

Brain Neoplasms, Lung Neoplasms

NCT04816838 2021-08-25

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Phase NA Unknown

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03257124 2021-08-16

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

80 enrolled

Non-Small Cell Lung Cancer With EGFR T790M Mutation

NCT04829019 2021-04-02

Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

88 enrolled

Neurocognitive

NCT03891615 2020-12-16

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Phase 1 Unknown

30 enrolled

Lung Neoplasms

NCT04575415 2020-10-20

BELLA

272 enrolled

NSCLC

NCT03532698 2020-07-23

Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)

100 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04425681 2020-06-11

OWBLM

20 enrolled

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04148898 2019-11-04

OWONBNSCLCLM

80 enrolled

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04029350 2019-08-21

ALTN-03

53 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02771314 2019-02-22

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02811354 2018-09-20

PLASMA

108 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03460275 2018-03-09

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03424759 2018-02-07

Uncommon EGFR AZD9291

37 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03050411 2017-02-10

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Phase 1 Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02972333 2016-11-23

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Phase 3 Unknown

150 enrolled